A narrative review assessed lipid nanoparticle approaches for tuberculosis drug delivery, focusing on how carrier benefits in preclinical systems translate—or fail to translate—into clinical utility. The review notes that lipid-based nanocarriers can improve drug exposure and macrophage uptake in animal models. However, it also details translational hurdles including bacterial resistance mechanisms and biological factors that limit real-world performance. The paper frames lipid-nanocarrier design constraints as central to the ongoing lack of clinical breakthrough delivery outcomes for TB therapies.